These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 220537)

  • 1. Reversal of vascular and renal crises of scleroderma by oral angiotensin-converting-enzyme blockade.
    Lopez-Ovejero JA; Saal SD; D'Angelo WA; Cheigh JS; Stenzel KH; Laragh JH
    N Engl J Med; 1979 Jun; 300(25):1417-9. PubMed ID: 220537
    [No Abstract]   [Full Text] [Related]  

  • 2. Failure of captopril to reverse the renal crisis of scleroderma.
    Brown EA; Macgregor GA; Maini RN
    Ann Rheum Dis; 1983 Feb; 42(1):52-3. PubMed ID: 6338841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Scleroderma renal crisis (SRC): hypertensive, normotensive].
    Endo H
    Nihon Rinsho Meneki Gakkai Kaishi; 2000 Dec; 23(6):656-60. PubMed ID: 11210764
    [No Abstract]   [Full Text] [Related]  

  • 4. Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man.
    Gavras H; Brunner HR; Turini GA; Kershaw GR; Tifft CP; Cuttelod S; Gavras I; Vukovich RA; McKinstry DN
    N Engl J Med; 1978 May; 298(18):991-5. PubMed ID: 205788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renin-angiotensin system in normotensive and hypertensive patients with progressive systemic sclerosis: hyporesponsiveness of renin during captopril test.
    Guillevin L; Leenhardt A; Godeau P
    Postgrad Med J; 1983; 59 Suppl 3():171-2. PubMed ID: 6359107
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of captopril (SQ 14225) on blood pressure, plasma renin activity and angiotensin I converting enzyme activity.
    Larochelle P; Genest J; Kuchel O; Boucher R; Gutkowska Y; McKinstry D
    Can Med Assoc J; 1979 Aug; 121(3):309-16. PubMed ID: 223756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is scleroderma renal crisis with anti-centromere antibody-positive limited cutaneous systemic sclerosis overlooked in patients with hypertension and/or renal dysfunction?
    Sugimoto T; Sanada M; Kashiwagi A
    Nephrology (Carlton); 2008 Apr; 13(2):179-80. PubMed ID: 18275510
    [No Abstract]   [Full Text] [Related]  

  • 8. [Progress on diagnosis and therapy of kidney diseases complicated with systemic scleroderma and dermatomyositis].
    Kondo H
    Nihon Naika Gakkai Zasshi; 1992 Jan; 81(1):18-21. PubMed ID: 1556456
    [No Abstract]   [Full Text] [Related]  

  • 9. Captopril in the treatment of scleroderma renal crisis.
    Thurm RH; Alexander JC
    Arch Intern Med; 1984 Apr; 144(4):733-5. PubMed ID: 6370160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Special uses for captopril.
    Materson BJ
    Am J Kidney Dis; 1987 Jul; 10(1 Suppl 1):88-93. PubMed ID: 2886046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of renal crisis in progressive systemic sclerosis with captopril].
    Latorre LC; Mion D; Zerbini CA; Pastor EH; Resende C; Fidelis TS; Gabriel Júnior A; Assad RL; Cossermelli W
    Rev Hosp Clin Fac Med Sao Paulo; 1985; 40(1):18-21. PubMed ID: 3903950
    [No Abstract]   [Full Text] [Related]  

  • 12. Variable response to oral angiotensin-converting-enzyme blockade in hypertensive scleroderma patients.
    Whitman HH; Case DB; Laragh JH; Christian CL; Botstein G; Maricq H; Leroy EC
    Arthritis Rheum; 1982 Mar; 25(3):241-8. PubMed ID: 6279117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Beneficial effect of the converting enzyme inhibitor on the acute renal failure of scleroderma with arterial hypertension].
    Mercatello A; Zech PY
    Nouv Presse Med; 1981 Apr; 10(19):1596. PubMed ID: 7025853
    [No Abstract]   [Full Text] [Related]  

  • 14. [Potentiation of the antihypertensive effect of captopril by diuretics (author's transl)].
    Waeber B; Brunner HR; Turini GA; Curtet N; Keller I; Gavras H
    Ann Cardiol Angeiol (Paris); 1979; 28(1):9-11. PubMed ID: 219758
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of angiotensin-converting-enzyme inhibitors in the management of renal disease.
    Asher JP; Murray KM
    Clin Pharm; 1991 Jan; 10(1):25-31. PubMed ID: 1999085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal Involvement in Systemic Sclerosis: An Update.
    Chrabaszcz M; Małyszko J; Sikora M; Alda-Malicka R; Stochmal A; Matuszkiewicz-Rowinska J; Rudnicka L
    Kidney Blood Press Res; 2020; 45(4):532-548. PubMed ID: 32521536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical experience with a new antihypertensive drug (captopril SQ 14.225), an oral inhibitor of converting enzyme].
    Santucci A; Aguglia F; Ficara C
    Clin Ter; 1981 Apr; 97(1):43-58. PubMed ID: 6269793
    [No Abstract]   [Full Text] [Related]  

  • 18. [Renal involvement in scleroderma].
    Boffa JJ; Rossert J
    Rev Prat; 2002 Nov; 52(17):1910-4. PubMed ID: 12532868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Acute inhibition of angiotensin-converting enzyme by captopril. Hemodynamic and biochemical aspects in normotension and essential hypertension].
    Stanek B; Templ H; Pohanka E; Silberbauer K
    Acta Med Austriaca; 1982; 9(5-6):175-80. PubMed ID: 6299046
    [No Abstract]   [Full Text] [Related]  

  • 20. [Chronic treatment of hypertension by an inhibitor of angiotensin converting enzyme].
    Waeber B; Gavras H; Brunner HR; Chappuis P; Turini GA
    Schweiz Med Wochenschr; 1978 Dec; 108(49):1981-3. PubMed ID: 219469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.